Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C78195
http://purl.obolibrary.org/obo/NCIT_C78195
|
|---|---|
| Preferred Name | Sonepcizumab |
| Definitions |
A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1). |
|---|---|
| prefLabel | Sonepcizumab
|
| label | Sonepcizumab
|
| NCI_META_CUI | CL383585
|
| PDQ_Closed_Trial_Search_ID | 595163
|
| code | C78195
|
| prefixIRI | NCIT:C78195
|
| in_subset | |
| Preferred_Name | Sonepcizumab
|
| FDA_UNII_Code | O4T5UXS4P2
|
| Contributing_Source | FDA
|
| Maps_To | Sonepcizumab
|
| CAS_Registry | 1031360-18-5
|
| NCI_Drug_Dictionary_ID | 595163
|
| Legacy Concept Name | Sonepcizumab
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 595163
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |